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Abstract: BACKGROUND Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been
shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and
ILD. METHODS We conducted a randomized, double-blind, placebo-controlled trial to investigate the
efficacy and safety of nintedanib in patients with ILD associated with systemic sclerosis. Patients who
had systemic sclerosis with an onset of the first non-Raynaud’s symptom within the past 7 years and a
high-resolution computed tomographic scan that showed fibrosis affecting at least 10% of the lungs were
randomly assigned, in a 1:1 ratio, to receive 150 mg of nintedanib, administered orally twice daily, or
placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed
over a 52-week period. Key secondary end points were absolute changes from baseline in the modified
Rodnan skin score and in the total score on the St. George’s Respiratory Questionnaire (SGRQ) at week
52. RESULTS A total of 576 patients received at least one dose of nintedanib or placebo; 51.9% had
diffuse cutaneous systemic sclerosis, and 48.4% were receiving mycophenolate at baseline. In the primary
end-point analysis, the adjusted annual rate of change in FVC was -52.4 ml per year in the nintedanib
group and -93.3 ml per year in the placebo group (difference, 41.0 ml per year; 95% confidence interval
[CI], 2.9 to 79.0; P = 0.04). Sensitivity analyses based on multiple imputation for missing data yielded
P values for the primary end point ranging from 0.06 to 0.10. The change from baseline in the modified
Rodnan skin score and the total score on the SGRQ at week 52 did not differ significantly between
the trial groups, with differences of -0.21 (95% CI, -0.94 to 0.53; P = 0.58) and 1.69 (95% CI, -0.73 to
4.12 [not adjusted for multiple comparisons]), respectively. Diarrhea, the most common adverse event,
was reported in 75.7% of the patients in the nintedanib group and in 31.6% of those in the placebo
group. CONCLUSIONS Among patients with ILD associated with systemic sclerosis, the annual rate
of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was
observed for other manifestations of systemic sclerosis. The adverse-event profile of nintedanib observed
in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal
adverse events, including diarrhea, were more common with nintedanib than with placebo. (Funded by
Boehringer Ingelheim; SENSCIS ClinicalTrials.gov number, NCT02597933.).
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BACKGROUND
Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a 
leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase inhibitor, 
has been shown to have antifibrotic and antiinflammatory effects in preclinical models 
of systemic sclerosis and ILD.
METHODS
We conducted a randomized, double-blind, placebo-controlled trial to investigate the effi-
cacy and safety of nintedanib in patients with ILD associated with systemic sclerosis. Patients 
who had systemic sclerosis with an onset of the first non-Raynaud’s symptom within the 
past 7 years and a high-resolution computed tomographic scan that showed fibrosis affect-
ing at least 10% of the lungs were randomly assigned, in a 1:1 ratio, to receive 150 mg of 
nintedanib, administered orally twice daily, or placebo. The primary end point was the an-
nual rate of decline in forced vital capacity (FVC), assessed over a 52-week period. Key sec-
ondary end points were absolute changes from baseline in the modified Rodnan skin score 
and in the total score on the St. George’s Respiratory Questionnaire (SGRQ) at week 52.
RESULTS
A total of 576 patients received at least one dose of nintedanib or placebo; 51.9% had 
diffuse cutaneous systemic sclerosis, and 48.4% were receiving mycophenolate at base-
line. In the primary end-point analysis, the adjusted annual rate of change in FVC was 
−52.4 ml per year in the nintedanib group and −93.3 ml per year in the placebo group 
(difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P = 0.04). Sensitiv-
ity analyses based on multiple imputation for missing data yielded P values for the pri-
mary end point ranging from 0.06 to 0.10. The change from baseline in the modified 
Rodnan skin score and the total score on the SGRQ at week 52 did not differ signifi-
cantly between the trial groups, with differences of −0.21 (95% CI, −0.94 to 0.53; P = 0.58) 
and 1.69 (95% CI, −0.73 to 4.12 [not adjusted for multiple comparisons]), respectively. 
Diarrhea, the most common adverse event, was reported in 75.7% of the patients in the 
nintedanib group and in 31.6% of those in the placebo group.
CONCLUSIONS
Among patients with ILD associated with systemic sclerosis, the annual rate of decline 
in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib 
was observed for other manifestations of systemic sclerosis. The adverse-event profile 
of nintedanib observed in this trial was similar to that observed in patients with idio-
pathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were 
more common with nintedanib than with placebo. (Funded by Boehringer Ingelheim; 
SENSCIS ClinicalTrials.gov number, NCT02597933.)
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Systemic sclerosis is a rare and het-erogeneous autoimmune disease character-ized by immune dysregulation, microvascu-
lar damage, and organ fibrosis.1 Interstitial lung 
disease (ILD) is a common manifestation of 
systemic sclerosis that tends to occur early in the 
course of disease2,3; the condition places a con-
siderable burden on patients and health care 
resources4,5 and is a leading cause of death re-
lated to systemic sclerosis.6 On the basis of evi-
dence from two randomized, double-blind trials 
(Scleroderma Lung Studies I and II [SLS-I and 
SLS-II]),7,8 the immunosuppressants mycopheno-
late and cyclophosphamide are frequently used 
for the treatment of ILD associated with systemic 
sclerosis. In addition, targeted treatments are 
licensed to address other organ manifestations 
such as pulmonary arterial hypertension and 
digital ulcers.
Nintedanib, an intracellular inhibitor of tyro-
sine kinases,9 is an approved treatment for idi-
opathic pulmonary fibrosis. In patients with 
idiopathic pulmonary fibrosis, treatment with 
nintedanib (150 mg twice daily) slowed disease 
progression by reducing the rate of decline of 
the forced vital capacity (FVC).10,11 Although idio-
pathic pulmonary fibrosis and ILD associated 
with systemic sclerosis have different triggers, 
the pathophysiological processes of both diseases 
include the transformation of fibroblasts to a 
myofibroblastic phenotype and the excess depo-
sition of extracellular matrix.12-15 Nintedanib has 
shown antifibrotic, antiinflammatory, and vascu-
lar remodeling effects in several animal models 
resembling aspects of systemic sclerosis, ILD 
associated with systemic sclerosis, and other 
fibrosing ILDs,9,15-21 findings that suggest that 
nintedanib could modulate processes funda-
mental to the progression of fibrosis in humans. 
We conducted the Safety and Efficacy of Ninted-
anib in Systemic Sclerosis (SENSCIS) trial to 
investigate the efficacy and safety of nintedanib 
in patients with ILD associated with systemic 
sclerosis.
Me thods
Trial Design and Oversight
The SENSCIS trial was a randomized, double-
blind, placebo-controlled, parallel-group trial that 
was performed in 32 countries.22 The trial was 
conducted in accordance with the trial protocol 
(available with the full text of this article at 
NEJM.org), the principles of the Declaration of 
Helsinki, and the Harmonized Tripartite Guide-
line for Good Clinical Practice from the Interna-
tional Conference on Harmonisation and was 
approved by local authorities. Written informed 
consent was obtained from all patients before 
study entry. The authors had access to the data, 
which were analyzed by the trial sponsor, Boeh-
ringer Ingelheim. The authors were fully respon-
sible for all content and editorial decisions, were 
involved at all stages of manuscript develop-
ment, and approved the final version for submis-
sion. The authors vouch for the accuracy and 
completeness of the data and for the fidelity of 
the trial to the protocol. The statistical analysis 
plan is available with the protocol at NEJM.org. 
Medical writing assistance, paid for by the spon-
sor, was provided by FleishmanHillard Fishburn.
Patients
Patients were recruited from November 2015 
through October 2017 and were eligible for en-
rollment if they were at least 18 years of age and 
had systemic sclerosis according to classification 
criteria of the American College of Rheumatol-
ogy and European League Against Rheumatism,1 
with an onset of the first non-Raynaud’s symp-
tom within 7 years before screening. ILD was 
identified on the basis of a high-resolution 
computed tomographic scan, obtained within 
12 months before screening, that showed fibro-
sis affecting at least 10% of the lungs, as con-
firmed by an expert radiologist at a central loca-
tion. Patients were required to have an FVC that 
was at least 40% of the predicted value and a 
diffusion capacity of the lung for carbon mon-
oxide (DLCO) (corrected for hemoglobin) that was 
30 to 89% of the predicted value. Patients who 
were receiving prednisone at a dose of up to 10 mg 
per day or mycophenolate or methotrexate at a 
stable dose for at least 6 months before random-
ization (or both therapies) could participate in 
the trial. If clinically significant worsening of 
systemic sclerosis occurred during the trial, ad-
ditional therapy was allowed (see section B in the 
Supplementary Appendix, available at NEJM.org). 
Key exclusion criteria are listed in section C in 
the Supplementary Appendix. Of the 819 patients 
screened, 4 who had clinically significant pul-
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monary hypertension (defined as previous clini-
cal or echocardiographic evidence of significant 
right heart failure, history of right heart cathe-
terization with a cardiac index of ≤2 liters per 
minute per square meter of body-surface area, or 
pulmonary hypertension that led to parenteral 
therapy with epoprostenol or treprostinil) were 
excluded.
Randomization and Procedures
After a screening period of 12 weeks or less, 
patients were randomly assigned, in a 1:1 ratio, 
to receive 150 mg of nintedanib, administered 
orally twice daily, or placebo. Randomization 
was performed with the use of an interactive 
response system, and the patients were stratified 
according to the presence of antitopoisomerase I 
antibody, which has been associated with a 
decline in FVC in patients with early systemic 
sclerosis.23 The primary efficacy evaluation was 
conducted at week 52. Patients continued to re-
ceive the assigned intervention in a blinded man-
ner until the last patient reached week 52 but for 
no longer than 100 weeks. Patients who discon-
tinued the intervention were asked to attend all 
scheduled visits and undergo examinations as 
originally planned. Patients who had adverse 
events were permitted to interrupt the course of 
their assigned intervention (for ≤4 weeks if they 
had an adverse event that was considered to be 
related to the intervention by the investigator or 
for ≤8 weeks for adverse events that were not 
considered to be related to the intervention) or 
to reduce the dose to 100 mg twice daily.
End Points
The primary end point was the annual rate of 
decline in FVC (milliliters per year), assessed over 
a 52-week period and analyzed with a random-
coefficient regression model. Key secondary end 
points were absolute changes from baseline in 
the modified Rodnan skin score and the total 
score on the St. George’s Respiratory Question-
naire (SGRQ) at week 52. The modified Rodnan 
skin score is used to evaluate a patient’s skin 
thickness through palpation of 17 areas; scores 
range from 0 to 3 for each area (to give a maxi-
mum score of 51), with higher scores indicating 
worse skin fibrosis.24,25 The minimal clinically 
important difference in modified Rodnan skin 
score in patients with ILD associated with sys-
temic sclerosis has not been established but has 
been suggested to be 3 to 4 points.26 The SGRQ 
is a 50-item questionnaire that is administered 
by the patients themselves. The questionnaire 
comprises three domains (symptoms, activity, 
and impact) that assess health-related quality of 
life in patients with respiratory disease.27 Domain 
and total scores range from 0 to 100, with higher 
scores indicating worse health-related quality of 
life. The minimal clinically important difference 
in SGRQ total score in patients with ILD associ-
ated with systemic sclerosis has not been estab-
lished, but a change of 4 points or more may 
represent a meaningful change in patients with 
idiopathic pulmonary fibrosis.28
Other prespecified secondary end points in-
cluded the annual rate of decline in FVC as a 
percentage of the predicted value; the absolute 
change from baseline in FVC (measured in milli-
liters) at week 52; the absolute change from 
baseline in DLCO as a percentage of the predicted 
value at week 52; the absolute changes from 
baseline in net digital ulcer burden (the number 
of fingers with ulcers of vascular origin distal to 
the proximal interphalangeal joints), score on the 
Health Assessment Questionnaire–Disability Index 
(HAQ-DI)29 and score on the Functional Assess-
ment of Chronic Illness Therapy (FACIT)–Dyspnea 
questionnaire30 at week 52; and the time to 
death from any cause (analyzed over the entire 
trial period). Scores on the HAQ-DI range from 
0 to 3, with higher scores indicating worse dis-
ability. The minimal clinically important differ-
ence in HAQ-DI score in patients with diffuse 
cutaneous systemic sclerosis has been estimated 
to be 0.10 to 0.14.31 The raw score on the FACIT-
Dyspnea questionnaire ranges from 0 to 30 and 
the scaled score from 27.7 to 75.9, with higher 
scores indicating worse dyspnea; no minimal 
clinically important difference has been estab-
lished for this tool. We also assessed categorical 
declines in FVC (the percentages of patients who 
had absolute declines from baseline in FVC of >5 
and >10 percentage points of the predicted value 
at week 52 and the percentages of patients who 
had relative declines from baseline in FVC [mea-
sured in milliliters] of >5% and >10% at week 52) 
as end points for response to intervention.
For the lung function end points listed above, 
spirometry was performed at baseline and at 
weeks 2, 4, 6, 12, 24, 36, and 52. Spirometers 
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were provided by the sponsor. Spirometry was 
performed in accordance with international guide-
lines.32 The results were confirmed by personnel 
at a central reading center. The assessments of 
the modified Rodnan skin score were conducted 
at baseline and at weeks 12, 24, 36, and 52. The 
SGRQ, HAQ-DI, and FACIT-Dyspnea question-
naire were completed at baseline and at weeks 
24 and 52. Safety was assessed from the first 
dose to 28 days after the last dose of the trial 
drug or placebo; assessments included clinical 
evaluation, laboratory measurements, and the 
recording of adverse events, coded according to 
the Medical Dictionary for Regulatory Activities, ver-
sion 21.1.
Statistical Analysis
All analyses were conducted in the patients who 
received at least one dose of the trial drug or 
placebo. The primary end point was analyzed 
with the use of a random-coefficient regression 
model (with random slopes and intercepts) that 
included effects of treatment, antitopoisomerase I 
antibody status (positive or negative), age, height, 
sex, baseline FVC (measured in milliliters), time, 
and treatment-by-time and baseline-by-time inter-
actions. The slope of the decline in FVC was 
calculated for every patient, and the average was 
compared between trial groups. The analysis 
was based on all measurements taken over a 
52-week period, including those from patients 
who discontinued the trial drug or placebo. The 
model allowed for missing data, with the as-
sumption that the data were missing at random. 
Sensitivity analyses, including those in which we 
used the approach of multiple imputation for 
missing data, and the statistical analysis of 
other end points are described in sections D and 
E, respectively, in the Supplementary Appendix. 
The primary and secondary end points were 
tested under a hierarchical test strategy that 
protected the type I error (see section F in the 
Supplementary Appendix).22 Significance tests 
were two-sided, with an alpha value of 0.05. The 
95% confidence intervals for the end points that 
were not covered by the hierarchical testing pro-
cedure were not adjusted for multiplicity. De-
scriptive statistics are presented for safety data.
In the calculation of the sample size, the dif-
ference in the absolute change from baseline in 
FVC at week 52 between the trial groups was 
assumed to be 70 to 110 ml, which reflects a 
reduction of approximately 50% on the basis of 
the results of SLS-I7 and the phase 3 INPULSIS 
trials involving patients with idiopathic pulmo-
nary fibrosis11 (in the absence of more appropri-
ate data from placebo groups). No assumptions 
were made with regard to the potential effect of 
concomitant immunosuppressive therapy. A sam-
ple size of 260 patients per trial group was esti-
mated to provide the trial 90% power to detect 
a between-group difference of 70 ml in the an-
nual rate of decline in FVC, with the assumption 
of a standard deviation of 245 ml in both groups.
R esult s
Patients
A total of 576 patients received at least one dose 
of nintedanib or placebo (Fig. 1). The baseline 
characteristics of the patients were similar be-
tween trial groups (Table 1; and see section G in 
the Supplementary Appendix). Approximately half 
the patients had diffuse cutaneous systemic scle-
rosis, and half had limited cutaneous systemic 
sclerosis (51.9% and 48.1%, respectively). The 
median time since the onset of the first non-
Raynaud’s symptom was 3.4 years. The mean 
(±SD) age of the patients was 54.0±12.2 years, 
and the mean FVC and DLCO were 72.5±16.7% 
and 53.0±15.1% of the predicted value, respec-
tively. The mean extent of fibrosis on high-reso-
lution computed tomography was 36.0±21.3%. 
Almost half (48.4%) of the patients were receiv-
ing mycophenolate at baseline.
Among the patients who received at least one 
dose, 232 (80.6%) in the nintedanib group and 
257 (89.2%) in the placebo group completed the 
52-week intervention, and FVC measurements at 
week 52 were available for 241 (83.7%) and 257 
(89.2%) patients, respectively. The mean duration 
of exposure to the trial drug or placebo from the 
first dose to week 52 (or to last dose in patients 
who discontinued the intervention before week 
52) was 10.5±3.4 months in the nintedanib group 
and 11.4±2.4 months in the placebo group.
Primary End Point and Secondary Lung 
Function End Points
The adjusted annual rate of change in FVC over 
a 52-week period was lower in the nintedanib 
group than in the placebo group (−52.4 ml per 
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year vs. −93.3 ml per year; difference, 41.0 ml 
per year; 95% confidence interval [CI], 2.9 to 
79.0; P = 0.04) (Fig. 2 and Table 2). Multiple-impu-
tation sensitivity analyses for missing data yield-
ed P values ranging from 0.06 to 0.10 (see section 
D in the Supplementary Appendix).
The curves for the change from baseline in 
FVC separated by week 12 and continued to di-
verge (Fig. 2C). The adjusted mean absolute 
change from baseline in FVC at week 52 was 
consistent with the result of the primary analysis: 
−54.6 ml in the nintedanib group and −101.0 ml 
in the placebo group (difference, 46.4 ml; 95% 
CI, 8.1 to 84.7) (Fig. 2 and Table 2). The adjusted 
mean annual rate of change in FVC as a percent-
age of the predicted value at week 52 was −1.4% 
in the nintedanib group and −2.6% in the pla-
cebo group (difference, 1.2 percentage points; 
95% CI, 0.1 to 2.2) (Table 2). The percentages of 
patients who had an absolute decline from base-
line in FVC of more than 5 percentage points of 
the predicted value at week 52 were 20.6% in the 
nintedanib group and 28.5% in the placebo 
group (odds ratio, 0.65; 95% CI, 0.44 to 0.96). 
The percentages of patients with a relative de-
cline in FVC (measured in milliliters) of more 
Figure 1. Enrollment, Randomization, and Follow-up.
580 Underwent randomization
4 Did not receive intervention
3 Underwent randomization but were not eligible
1 Withdrew consent
819 Patients were assessed for eligibility
239 Were excluded
196 Did not meet inclusion criteria
or met exclusion criteria
23 Withdrew consent
2 Had an adverse event
18 Had other or unknown reason
288 Were assigned to receive nintedanib,
150 mg twice daily
232 Did not prematurely
discontinue the intervention
before wk 52
56 Prematurely discontinued
the intervention 
40 Had adverse event
9 Refused to continue taking
assigned intervention
1 Did not adhere to protocol
6 Had other reason
288 Were assigned to receive placebo
24 Did not complete
visits up to wk 52
13 Did not complete
visits up to wk 52
257 Did not prematurely
discontinue the intervention
before wk 52
31 Prematurely discontinued
the intervention
21 Had adverse event
7 Refused to continue taking
assigned intervention
1 Did not adhere to protocol
2 Had other reason
264 Completed visits up to wk 52 275 Completed visits up to wk 52
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than 10% at week 52 were 16.7% in the ninted-
anib group and 18.1% in the placebo group 
(odds ratio, 0.91; 95% CI, 0.59 to 1.41). A forest 
plot of prespecified subgroups, along with the 
P values for the treatment-by-time-by-subgroup 
interactions, is shown in section H in the Sup-
plementary Appendix. The annual rates of change 
in FVC among the patients who were receiving 
mycophenolate at baseline were −40.2 ml per 
year in the nintedanib group and −66.5 ml per 
year in the placebo group, and the correspond-
ing rates among the patients who were not re-
ceiving mycophenolate at baseline were −63.9 ml 
per year and −119.3 ml per year.
Characteristic
Nintedanib 
(N = 288)
Placebo 
(N = 288)
Female sex — no. (%) 221 (76.7) 212 (73.6)
Age — yr 54.6±11.8 53.4±12.6
Diffuse cutaneous systemic sclerosis — no. (%) 153 (53.1) 146 (50.7)
Years since the onset of the first non-Raynaud’s symptom
Median 3.4 3.5
Range 0.3 to 7.1 0.4 to 7.2
Extent of fibrosis of the lungs on high-resolution CT — % 36.8±21.8 35.2±20.7
FVC — ml 2459±736 2541±816
FVC — % of predicted value 72.4±16.8 72.7±16.6
DLCO — % of predicted value† 52.9±15.1 53.2±15.1
Antitopoisomerase antibody positive — no. (%)‡ 173 (60.1) 177 (61.5)
Modified Rodnan skin score§ 11.3±9.2 10.9±8.8
Patients with diffuse cutaneous systemic sclerosis 17.0±8.7 16.3±8.9
Patients with limited cutaneous systemic sclerosis 4.9±4.2 5.4±4.1
Total score on the SGRQ¶ 40.7±20.2 39.4±20.9
Score on the HAQ-DI‖ 0.65±0.70 0.55±0.58
Scaled score on the FACIT-Dyspnea questionnaire** 47.01±9.64 45.67±9.90
Receiving mycophenolate — no. (%) 139 (48.3) 140 (48.6)
Receiving methotrexate — no. (%) 23 (8.0) 15 (5.2)
*  Plus–minus values are means ±SD. Data on some variables were not available for all patients. A larger table of base-
line characteristics is included in section G in the Supplementary Appendix. CT denotes computed tomography, 
DLCO diffusion capacity of the lungs for carbon monoxide, FACIT Functional Assessment of Chronic Illness Therapy, 
FVC forced vital capacity, HAQ-DI Health Assessment Questionnaire–Disability Index, and SGRQ St. George’s 
Respiratory Questionnaire.
†  The DLCO value was corrected for the hemoglobin level. DLCO values were available for 285 patients in the nintedanib 
group and 284 patients in the placebo group.
‡  Historical information on antitopoisomerase antibody status was used, or, if this information was not available to the 
trial sites, it was provided by a central laboratory.
§  The modified Rodnan skin score is used to evaluate a patient’s skin thickness through palpation of 17 areas; scores 
range from 0 to 3 for each area (to give a maximum score of 51), with higher scores indicating worse skin fibrosis. 
Scores were available for 288 patients in the nintedanib group and 286 patients in the placebo group. Among the pa-
tients with diffuse cutaneous systemic sclerosis, scores were available for 153 of those in the nintedanib group and 
for 144 of those in the placebo group. Among the patients with limited cutaneous systemic sclerosis, scores were 
available for 135 of those in nintedanib group and for 142 of those in placebo group.
¶  Total scores on the SGRQ range from 0 to 100, with higher scores indicating worse health-related quality of life. 
Scores were available for 282 patients in the nintedanib group and 283 patients in the placebo group.
‖  Scores on the HAQ-DI range from 0 to 3, with higher scores indicating worse disability. Scores were available for 283 
patients in the nintedanib group and 281 patients in the placebo group.
**  Scaled scores on the FACIT-Dyspnea questionnaire range from 27.7 to 75.9, with higher scores indicating worse dys-
pnea. Scores were available for 283 patients in the nintedanib group and 285 patients in the placebo group.
Table 1. Baseline Characteristics of the Patients.*
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 Key Secondary End Points
The adjusted mean absolute change from base-
line in modified Rodnan skin score at week 52 
was −2.17 in the nintedanib group and −1.96 in 
the placebo group (difference, −0.21; 95% CI; 
−0.94 to 0.53). The adjusted mean absolute 
change from baseline in total score on the SGRQ 
at week 52 was 0.81 in the nintedanib group and 
−0.88 in the placebo group (difference, 1.69; 
95% CI, −0.73 to 4.12). Prespecified subgroup 
analyses showed that the results for the key sec-
ondary end points did not differ significantly 
Figure 2. Decline in Forced Vital Capacity.
Panel A shows the between-group adjusted difference in the annual rate of decline in forced vital capacity (FVC) over 52 weeks. I bars 
indicate the standard error. Panel B shows box and whisker plots of the adjusted annual rates of decline in FVC over 52 weeks (based on 
rates calculated from the primary model for each patient) in the nintedanib group and the placebo group. Q1 denotes the first quartile, 
and Q3 the third quartile. The whiskers are drawn from the box to the most extreme point that is less than or equal to 1.5 times the in-
terquartile range. The means differ slightly from the mean adjusted rates by treatment group estimated from the primary model shown 
in Panel A because of differences in covariate adjustment and handling of missing data. Panel C shows the observed change from base-
line over time in FVC. I bars indicate the standard error.
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among the patients with different baseline char-
acteristics (P>0.05 for the treatment-by-visit-by-
subgroup interactions), as shown in sections I 
and J in the Supplementary Appendix.
HAQ-DI and FACIT-Dyspnea Score
The difference in the absolute change from 
baseline in the score on the HAQ-DI at week 52 
between the nintedanib group and the placebo 
group was 0.032 (95% CI, −0.035 to 0.099). The 
difference in the absolute change from baseline 
in the FACIT-Dyspnea score at week 52 between 
trial groups was 0.64 (95% CI, −0.51 to 1.79) 
(see section K in Supplementary Appendix).
Adverse Events
The percentages of patients with any adverse 
event and any serious adverse event were similar 
in the nintedanib group and the placebo group 
(Table 3). The percentage of patients who had an 
adverse event that led to the discontinuation 
of the assigned intervention was higher in the 
nintedanib group than in the placebo group 
(16.0% vs. 8.7%). The most common adverse 
event was diarrhea, which was reported in 75.7% 
of the patients in the nintedanib group and in 
31.6% of the patients in the placebo group. 
Among the nintedanib-treated patients who had 
an adverse event of diarrhea, 49.5% had events 
that were classified as mild (at worst) in inten-
sity and 45.0% had events that were classified as 
moderate (at worst). Elevations in alanine amino-
transferase level, aspartate aminotransferase level, 
or both to at least three times the upper limit of 
the normal range were reported in 4.9% of the 
patients in the nintedanib group and in 0.7% of 
End Point Nintedanib Placebo
Difference 
(95% CI)
Primary end point
Annual rate of decline in FVC assessed over 52 weeks — ml/yr −52.4±13.8 −93.3±13.5 41.0 (2.9 to 79.0)†
Key secondary end points
Absolute change from baseline in modified Rodnan skin score at week 52 −2.17±0.27 −1.96±0.26 −0.21 (−0.94 to 0.53)‡
Absolute change from baseline in total score on the SGRQ at week 52 0.81±0.88 −0.88±0.87 1.69 (−0.73 to 4.12)§
Other secondary end points
Absolute change from baseline in FVC at week 52 — ml −54.6±13.9 −101.0±13.6 46.4 (8.1 to 84.7)§
Annual rate of decline in FVC — % of predicted value −1.4±0.4 −2.6±0.4 1.2 (0.1 to 2.2)§
Absolute change from baseline in DLCO at week 52 — % of predicted value −3.21±0.54 −2.77±0.54 −0.44 (−1.94 to 1.06)§
Absolute change from baseline in net digital ulcer burden at week 52 0.03±0.05 0.06±0.04 −0.03 (−0.16 to 0.09)§
Patients with an absolute decline from baseline in FVC of >5 percentage 
points of the predicted value at week 52 — no./total no. (%)
59/287 (20.6) 82/288 (28.5) 0.65 (0.44 to 0.96)§¶
Patients with an absolute decline from baseline in FVC of >10 percentage 
points of the predicted value at week 52 — no./total no. (%)
20/287 (7.0) 24/288 (8.3) 0.82 (0.44 to 1.52)§¶
Patients with a relative decline from baseline in FVC, measured in millili-
ters, of >5% at week 52 — no./total no. (%)
95/287 (33.1) 125/288 (43.4) 0.65 (0.46 to 0.91)§¶
Patients with a relative decline from baseline in FVC, measured in millili-
ters, of >10% at week 52 — no./total no. (%)
48/287 (16.7) 52/288 (18.1) 0.91 (0.59 to 1.41)§¶
*  Changes from baseline are adjusted means ±SE based on the statistical models. Data on some variables were not available for all patients. 
FVC end points were analyzed in 287 patients in the nintedanib group and 288 patients in the placebo group, except for the absolute change 
from baseline in FVC in milliliters, which was analyzed in 288 patients in both groups. Modified Rodnan skin score was analyzed in 288 pa-
tients in the nintedanib group and 286 patients in the placebo group, total score on the SGRQ in 282 and 283 patients, DLCO in 285 and 
284 patients, and net digital ulcer burden (the number of fingers with ulcers of vascular origin distal to the proximal interphalangeal joints) 
in 288 patients in both groups.
†  P = 0.04.
‡  P = 0.58.
§  The 95% confidence interval was not adjusted for multiple comparisons.
¶  The difference was assessed as an odds ratio.
Table 2. Primary and Secondary Efficacy End Points.*
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those in the placebo group. No patients met 
criteria for Hy’s law (serum alanine aminotrans-
ferase or aspartate aminotransferase level of more 
than three times the upper limit of the normal 
range and bilirubin level of more than two times 
the upper limit of the normal range without an 
identifiable cause).
Mortality
Over the entire trial period, 10 patients (3.5%) in 
the nintedanib group and 9 patients (3.1%) in 
the placebo group died (hazard ratio, 1.16; 95% 
CI, 0.47 to 2.84). Causes of death are listed in 
section L in the Supplementary Appendix.
Discussion
The SENSCIS trial was a large randomized, 
double-blind trial involving patients with ILD 
associated with systemic sclerosis. The results 
showed that the rate of decline in FVC over 52 
weeks among patients with ILD associated with 
systemic sclerosis was lower for those who re-
ceived nintedanib than for those who received 
placebo. Sensitivity analyses of this end point 
based on multiple imputation for missing data 
yielded P values ranging from 0.06 to 0.10. Sys-
temic sclerosis–associated ILD has a variable 
course, but many patients with this condition 
have progression of disease, with a decline in 
FVC that is associated with death.33-35 Although 
the annual rate of decline in FVC among the 
patients who received placebo in our trial was 
lower than that observed among the patients 
with idiopathic pulmonary fibrosis who received 
placebo in the INPULSIS trials11 (−93.3 ml in our 
trial vs. −223.5 ml in the INPULSIS trials), the 
relative effect of nintedanib as compared with 
placebo on reducing the rate of decline in FVC 
was similar (44% vs. 49%, respectively). In our 
trial and SLS-I,7 the difference between active 
treatment and placebo in the observed change 
from baseline in FVC as a percentage of the pre-
dicted value were in the same range. The abso-
lute between-group difference in the annual rate 
of decline in FVC observed in our trial (41 ml in 
favor of the nintedanib group) was smaller than 
assumed in the sample-size calculation. We spec-
ulate that this was because approximately half of 
the trial population were receiving mycopheno-
late at baseline and approximately half had lim-
ited cutaneous systemic sclerosis. This resulted 
in a trial population in which the decline in FVC 
in the placebo group was lower than assumed 
on the basis of historical data. The decline in 
FVC in the placebo group, as well as the magni-
tude of the effect of nintedanib, differed depend-
ing on mycophenolate use. Despite the large vari-
ability associated with the adjusted annual rates 
of decline in FVC observed in the current trial 
and the limitations inherent in comparing groups 
of patients who had not undergone randomiza-
tion according to mycophenolate use, these data 
suggest a potential benefit of mycophenolate on 
lung function.
The SENSCIS trial involved a broad range of 
Event
Nintedanib 
(N = 288)
Placebo 
(N = 288)
no. of patients (%)
Any adverse event 283 (98.3) 276 (95.8)
Most common adverse events†
Diarrhea 218 (75.7) 91 (31.6)
Nausea 91 (31.6) 39 (13.5)
Skin ulcer 53 (18.4) 50 (17.4)
Vomiting 71 (24.7) 30 (10.4)
Cough 34 (11.8) 52 (18.1)
Nasopharyngitis 36 (12.5) 49 (17.0)
Upper respiratory tract infection 33 (11.5) 35 (12.2)
Abdominal pain 33 (11.5) 21 (7.3)
Fatigue 31 (10.8) 20 (6.9)
Weight decrease 34 (11.8) 12 (4.2)
Severe adverse event‡ 52 (18.1) 36 (12.5)
Serious adverse event§ 69 (24.0) 62 (21.5)
Fatal adverse event 5 (1.7) 4 (1.4)
Adverse event leading to discontinuation  
of the intervention
46 (16.0) 25 (8.7)
*  Adverse events, as reported over 52 weeks plus a 28-day post-treatment peri-
od, were coded according to the preferred terms in the Medical Dictionary of 
Regulatory Activities. Data are shown for the patients who had at least one 
such adverse event.
†  The most common adverse events were those that were reported in more 
than 10% of the patients in either trial group.
‡  A severe adverse event was defined as an event that was incapacitating or that 
caused an inability to work or to perform usual activities.
§  A serious adverse event was defined as an event that resulted in death, was 
life-threatening, resulted in hospitalization or prolongation of hospitalization, 
resulted in persistent or clinically significant disability or incapacity, was a 
congenital anomaly or birth defect, or was deemed to be serious for any other 
reason.
Table 3. Adverse Events.*
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patients with ILD associated with systemic scle-
rosis, making the results relevant for the major-
ity of patients with this condition. However, 
because we excluded patients with clinically sig-
nificant pulmonary hypertension, our data can-
not be applied to such patients. The lower rate of 
decline in FVC in the nintedanib group was not 
accompanied by a benefit with respect to health-
related quality of life. No treatment effect was 
observed with respect to skin fibrosis, as assessed 
with the use of the modified Rodnan skin score. 
The modified Rodnan skin score improved in 
both trial groups, reflecting the natural course 
of skin fibrosis in patients with systemic sclero-
sis a few years after the onset of disease. Al-
though training was provided to all investiga-
tors, the limitations of the modified Rodnan 
skin score as a semiquantitative end point in 
large international trials should also be consid-
ered. No effect of nintedanib was observed with 
respect to patient-reported outcomes. Thus, while 
the results of the current trial suggest that nint-
edanib is effective in reducing the decline in FVC 
in patients with ILD associated with systemic 
sclerosis, this trial does not support nintedanib 
as a disease-modifying agent for systemic sclero-
sis as a whole (i.e., nintedanib does not address 
other organ complications).
The safety and adverse-event profile of nin-
tedanib in the SENSCIS trial was similar to pro-
files observed in the INPULSIS trials,11 although, 
as might be expected, gastrointestinal adverse 
events were more common in patients with ILD 
associated with systemic sclerosis than in those 
with idiopathic pulmonary fibrosis in both the 
active-drug and placebo groups. Although the per-
centage of patients who discontinued the assigned 
intervention because of adverse events was high-
er in the nintedanib group than in the placebo 
group, the percentage of those who discontin-
ued the assigned intervention because of adverse 
events was lower in the current trial than in the 
INPULSIS trials11 and more than 80% of the 
patients continued to receive nintedanib for 52 
weeks. Given the potential adverse effects that 
vascular endothelial growth factor receptor in-
hibitors have on wound healing,36 we note that 
there was no between-group difference in net 
digital ulcer burden.
In conclusion, the results of the SENSCIS 
trial showed that nintedanib has a beneficial ef-
fect by reducing the rate of decline in FVC in 
patients with ILD associated with systemic scle-
rosis over a 1-year period. In this trial, no other 
clinical benefit was observed. An uncontrolled 
open-label extension study (ClinicalTrials.gov 
number, NCT03313180) is ongoing and will pro-
vide long-term data on nintedanib therapy in pa-
tients with ILD associated with systemic sclerosis.
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